Find out more about the requirements cOAlition S plans to set for ‘transformative journals’.
With widespread and growing support for increased data sharing, what can we learn from the Yale Open Data Access (YODA) Project and its collaboration with Johnson & Johnson?
UNESCO uses this year’s World Science Day for Peace and Development to examine global disparities in open science.
Tim Ellison, Senior Medical Writer at Oxford PharmaGenesis, discusses a study into the open access policies of leading medical journals
Jackie Marchington, Director of Global Operations at Caudex, discusses good practice for conference abstracts and presentations
An analysis of data sharing statements reveals that open data may lead to a citation advantage.
Following the revised guidance on Plan S, Bernd Pulverer questions whether cOAlition S is making the most of the opportunity to push for open science.
A new tool from MPIP provides easily accessible information on open access options for industry-funded research.
Open source software is often used in science but is left uncited in many publications: researchers urge authors to make a change.
There are a number of publishing features to consider when selecting a journal. Find out how researchers are navigating the options to their best advantage.
Article processing charges are increasing, but a recent study finds that higher charges seem to attract rather than deter authors from submitting to open access journals.
Discover the five areas for improvement identified in Springer Nature’s recent surveys of researchers, aiming to promote data sharing.
ISMPP’s first white paper, ‘A multistakeholder discussion on open access and medical publishing’ is now available.
A recent article from The Chronicle of Higher Education discusses the potential benefits associated with journals that are established by funding bodies.
Feedback on the implementation guidance for Plan S highlights key themes for consideration.
Many public funders have mandated open access to their research and support Plan S. Should pharmaceutical companies follow suit?